Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CSTL
stocks logo

CSTL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
76.22M
-11.69%
-0.344
-207.42%
75.54M
-14.14%
-0.490
-45.56%
81.88M
-5%
-0.365
-343.33%
Estimates Revision
The market is revising Upward the revenue expectations for Castle Biosciences, Inc. (CSTL) for FY2025, with the revenue forecasts being adjusted by 4.83% over the past three months. During the same period, the stock price has changed by 68.17%.
Revenue Estimates for FY2025
Revise Upward
up Image
+4.83%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-39.82%
In Past 3 Month
Stock Price
Go Up
up Image
+68.17%
In Past 3 Month
Wall Street analysts forecast CSTL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSTL is 34.39 USD with a low forecast of 23.56 USD and a high forecast of 41.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast CSTL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSTL is 34.39 USD with a low forecast of 23.56 USD and a high forecast of 41.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 39.620
sliders
Low
23.56
Averages
34.39
High
41.00
Current: 39.620
sliders
Low
23.56
Averages
34.39
High
41.00
Baird
NULL -> Outperform
maintain
$39 -> $41
2025-11-04
Reason
Baird
Price Target
$39 -> $41
2025-11-04
maintain
NULL -> Outperform
Reason
Baird raised the firm's price target on Castle Biosciences to $41 from $39 and keeps an Outperform rating on the shares. The firm updated its model following solid Q3 results and raised revenue outlook.
Scotiabank
Outperform
downgrade
$44 -> $40
2025-05-21
Reason
Scotiabank
Price Target
$44 -> $40
2025-05-21
downgrade
Outperform
Reason
Scotiabank lowered the firm's price target on Castle Biosciences to $40 from $44 and keeps an Outperform rating on the shares. The company raised its full year guidance despite DecisionDx-SCC no longer being reimbursed by Medicare and the discontinuation of IDgenetix, the analyst tells investors. The company remains on track to launch a therapy guidance test for atopic dermatitis by the end of 2025, the firm adds.
Baird
Catherine Ramsey
Buy
Maintains
$36 → $37
2025-02-28
Reason
Baird
Catherine Ramsey
Price Target
$36 → $37
2025-02-28
Maintains
Buy
Reason
Stephens & Co.
Mason Carrico
Buy
Reiterates
$41
2025-01-02
Reason
Stephens & Co.
Mason Carrico
Price Target
$41
2025-01-02
Reiterates
Buy
Reason
Stephens analysts presented the firm's 2025 Best Ideas list, which includes Valley National (VLY), CoStar Group (CSGP), Castle Biosciences (CSTL), Alignment Healthcare (ALHC), Privia Health (PRVA), Vulcan Materials (VMC), South State (SSB), Matson (MATX), Azenta (AZTA), Prog Holdings (PRG), Carvana (CVNA), Blueprint Medicines (BPMC), Truist Financial (TFC), Cognex (CGNX), Fiserv (FI), Hancock Whitney (HWC), SunOpta (STKL), Wingstop (WING), SM Energy (SM), The Andersons (ANDE) and Bank of Marin (BMRC).
See All Ratings

Valuation Metrics

The current forward P/E ratio for Castle Biosciences Inc (CSTL.O) is -27.51, compared to its 5-year average forward P/E of -20.54. For a more detailed relative valuation and DCF analysis to assess Castle Biosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-20.54
Current PE
-27.51
Overvalued PE
5.66
Undervalued PE
-46.75

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-16.08
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.34
Undervalued EV/EBITDA
-33.50

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
6.26
Current PS
0.00
Overvalued PS
12.46
Undervalued PS
0.06
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CSTL News & Events

Events Timeline

(ET)
2025-11-14
07:10:00
Castle Biosciences Reveals Updated Findings on DecisionDx-Melanoma Test
select
2025-11-03 (ET)
2025-11-03
16:45:34
Castle Biosciences increases FY25 revenue forecast to $327M-$335M, up from $310M-$320M
select
2025-11-03
16:44:22
Castle Biosciences announces Q3 adjusted earnings per share of 2 cents, falling short of consensus estimate of 51 cents.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-24NASDAQ.COM
FDA Greenlights MRK's Keytruda and Keytruda SC Combination for Bladder Cancer Treatment

  • FDA Approvals: Merck received FDA approval for both intravenous and subcutaneous formulations of Keytruda in combination with Padcev for treating muscle-invasive bladder cancer in patients ineligible for cisplatin-based chemotherapy.

  • Clinical Trial Results: The approvals were based on the phase III KEYNOTE-905 trial, which demonstrated a 60% reduction in event-free survival events and a 50% improvement in overall survival when using Keytruda plus Padcev compared to surgery alone.

  • Market Performance: Despite the positive news, Merck's shares have declined by 1.7% year-to-date, contrasting with a 16.1% rise in the industry, while Keytruda continues to be a significant revenue driver for the company.

  • Competitor Insights: Other biotech stocks like CorMedix and Castle Biosciences have shown strong performance and positive earnings estimates, with Zacks ranking them higher than Merck, which currently holds a Zacks Rank #3 (Hold).

[object Object]
Preview
9.0
11-19NASDAQ.COM
Insmed Shares Climb Following EU Approval of Lung Disease Treatment, Brinsupri

  • Approval of Brinsupri: The European Commission has approved Brinsupri (brensocatib) for treating non-cystic fibrosis bronchiectasis (NCFB) in patients aged 12 and older, making it the first approved treatment for this condition in the EU.

  • Positive Clinical Data: Clinical studies demonstrated that Brinsupri significantly reduced the annual exacerbation rate and improved lung function in patients, supporting its approval under the EMA’s accelerated assessment pathway.

  • Market Performance: Following the approval, Insmed's shares rose by 2.1%, and the company has seen a 192% increase in stock value year-to-date, compared to a 15.7% rise in the industry.

  • Future Developments: Insmed is also exploring Brinsupri for other indications, including chronic rhinosinusitis and hidradenitis suppurativa, with data readouts expected in early to mid-2026.

[object Object]
Preview
6.5
11-17NASDAQ.COM
Zacks.com Spotlights Perimeter Solutions, Interface, Castle Biosciences, and Great Lakes Dredge & Dock

  • Investment Focus: The article highlights four stocks—Perimeter Solutions, Interface, Castle Biosciences, and Great Lakes Dredge & Dock—that are recommended for investors seeking companies with increasing cash flows, rather than focusing solely on profit margins.

  • Importance of Cash Flow: It emphasizes that positive and increasing cash flow is crucial for a company's resilience and growth potential, especially in uncertain economic conditions, as it indicates effective management and less reliance on external financing.

  • Stock Performance Insights: Each of the featured companies has shown upward revisions in earnings estimates, reflecting analysts' optimism about their future performance, with specific earnings projections provided for each stock.

  • Research Tools: The article promotes the Research Wizard stock picking and back-testing software as a valuable resource for investors to identify and evaluate stocks based on cash flow and other financial metrics.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Castle Biosciences Inc (CSTL) stock price today?

The current price of CSTL is 39.62 USD — it has increased 0.53 % in the last trading day.

arrow icon

What is Castle Biosciences Inc (CSTL)'s business?

Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.

arrow icon

What is the price predicton of CSTL Stock?

Wall Street analysts forecast CSTL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSTL is 34.39 USD with a low forecast of 23.56 USD and a high forecast of 41.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Castle Biosciences Inc (CSTL)'s revenue for the last quarter?

Castle Biosciences Inc revenue for the last quarter amounts to 83.04M USD, decreased -3.19 % YoY.

arrow icon

What is Castle Biosciences Inc (CSTL)'s earnings per share (EPS) for the last quarter?

Castle Biosciences Inc. EPS for the last quarter amounts to -0.02 USD, decreased -125.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Castle Biosciences Inc (CSTL)'s fundamentals?

The market is revising Upward the revenue expectations for Castle Biosciences, Inc. (CSTL) for FY2025, with the revenue forecasts being adjusted by 4.83% over the past three months. During the same period, the stock price has changed by 68.17%.
arrow icon

How many employees does Castle Biosciences Inc (CSTL). have?

Castle Biosciences Inc (CSTL) has 761 emplpoyees as of December 05 2025.

arrow icon

What is Castle Biosciences Inc (CSTL) market cap?

Today CSTL has the market capitalization of 1.15B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free